153248-46-5

Usage

Uses

Used in Pharmaceutical Industry:
1-Hydroxymethyl-1-(tert-butoxycarbonylaminomethyl)cyclopropane is used as a key reactant for the synthesis of imidazolylalkylamine compounds, which are of significant interest in the pharmaceutical industry. These imidazolylalkylamine compounds are specifically designed to inhibit human glutaminyl cyclase, an enzyme that plays a crucial role in the post-translational modification of proteins. Inhibition of this enzyme can have therapeutic implications in the treatment of various diseases and disorders related to protein misfolding and aggregation.
Used in Chemical Synthesis:
In the field of chemical synthesis, 1-Hydroxymethyl-1-(tert-butoxycarbonylaminomethyl)cyclopropane serves as an important building block for the creation of more complex organic molecules. Its unique structure allows for further functionalization and modification, making it a valuable asset in the development of new drugs, materials, and other specialty chemicals.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 45434-02-4 (1-(aminomethyl)cyclopropyl)methanol 
• 3697-69-6 ethyl 1-(cyanomethyl)cyclopropanecarboxylate 
• 1558-81-2 1-carbethoxy-1-cyanocyclopropane 
• 220145-17-5 methyl (<<(tert-butoxy)carbonyl>amino>methyl)cyclopropane-1-carboxylate 
• 204376-48-7 1-(<<(tert-butoxy)carbonyl>amino>methyl)cyclopropane-1-carboxylic acid 
• 6914-80-3 1-(aminocarbonyl)-1-cyclopropanecarboxylic acid methyl ester 

Downstream Products

• 877204-21-2 (1-((1H-imidazol-1-yl)methyl)cyclopropyl)methanamine 
• 153248-47-6 tert-butyl ((1-formylcyclopropyl)methyl)carbamate 

Relevant academic research and scientific papers

TRICYCLIC COMPOUNDS AND THEIR USE

Tricyclic compounds and their use are provided. More specifically, tricyclic compounds, pharmaceutical compositions containing them, methods for preparing them, and their use in therapy are also provided.

5-AMINO-4-CARBAMOYL-PYRAZOLE COMPOUNDS AS SELECTIVE AND IRREVERSIBLE T790M OVER WT-EGFR KINASE INHIBITORS AND USE THEREOF????

Disclosed are compounds of Formula (I), pharmaceutical compositions comprising the same, processes for the preparation thereof, and the use thereof.

SGC STIMULATORS

Compounds of Formulae (I') and (I) are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE

Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Ql, Q2, Rl, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.